title: Do antibodies to the hepatitis G virus E2 antigen in immunoglobulin products reduce infectivity?
authors.forename: K
authors.initials: K
authors.lastname: Cristiano
authors.forename: G
authors.initials: G
authors.lastname: Bisso
authors.forename: M
authors.initials: M
authors.lastname: Wirz
authors.forename: G
authors.initials: G
authors.lastname: Gentili
mesh_terms: D004340:Drug Contamination; D006508:Hepatitis Antibodies / Q000097:blood*; D018963:Hepatitis Antigens / Q000276:immunology*; D006525:Hepatitis, Viral, Human / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D006508:Hepatitis Antibodies; D018963:Hepatitis Antigens; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D008562:Membrane Glycoproteins; D014759:Viral Envelope Proteins; C107619:glycoprotein E2, GB virus C